ACM

Aisling Capital Management Portfolio holdings

AUM $360M
This Quarter Return
+90.99%
1 Year Return
+114.67%
3 Year Return
+1,171.46%
5 Year Return
+892.24%
10 Year Return
–
AUM
$208M
AUM Growth
+$208M
Cap. Flow
-$6.37M
Cap. Flow %
-3.06%
Top 10 Hldgs %
97.46%
Holding
16
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

1
VRNA
Verona Pharma
VRNA
$4.36M
2
MRKR icon
Marker Therapeutics
MRKR
$2.01M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$9.89B
$101M 48.41% 6,068,125 – –
BMEA icon
2
Biomea Fusion
BMEA
$116M
$24.8M 11.92% 798,757 – –
VRNA
3
Verona Pharma
VRNA
$9.16B
$22.4M 10.78% 1,115,352 -217,133 -16% -$4.36M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.41B
$21.6M 10.42% 1,025,000 – –
GLUE icon
5
Monte Rosa Therapeutics
GLUE
$296M
$11.5M 5.52% 1,472,331 – –
ELEV
6
DELISTED
Elevation Oncology
ELEV
$5.39M 2.59% 2,834,910 – –
OKUR
7
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
$5.3M 2.55% 886,075 – –
NUVB icon
8
Nuvation Bio
NUVB
$1.02B
$4.22M 2.03% 2,541,009 – –
ACRS icon
9
Aclaris Therapeutics
ACRS
$209M
$3.51M 1.69% 434,455 – –
PSTX
10
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$3.21M 1.55% 1,043,267 – –
SPRB
11
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
$2.66M 1.28% 1,205,511 – –
TECX
12
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
$1.01M 0.49% 1,009,779 – –
SYRE icon
13
Spyre Therapeutics
SYRE
$996M
$490K 0.24% 1,691,151 – –
VIRX
14
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$459K 0.22% 288,571 – –
BCEL
15
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$442K 0.21% 387,653 – –
MRKR icon
16
Marker Therapeutics
MRKR
$12M
$223K 0.11% 314,286 -2,828,571 -90% -$2.01M